Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-({6-[(4-cyanobenzyl)oxy]naphthalen-2-yl}sulfonyl)-D-glutamic acid is a synthetic small molecule compound containing a naphthalene ring substituted with a 4-cyanobenzyl ether and sulfonamide group attached to D-glutamic acid. It belongs to the class of glutamic acid derivatives. The compound is catalogued as CHEMBL458966 and has been referenced in chemical databases, but there is no evidence of clinical development, approved indications, or detailed mechanism of action in the public domain[1][2][3][9]. Its primary use appears to be experimental or as a research tool.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-({6-[(4-cyanobenzyl)oxy]naphthalen-2-yl}sulfonyl)-D-glutamic acid.